What does AMBROISE Vincent, médecine générale do?

AMBROISE Vincent, médecine générale is a general practice in Rouvroy. Private Limited, started on 7 November 2019, 1 establishment.

What is the address of AMBROISE Vincent, médecine générale?

The registered office of AMBROISE Vincent, médecine générale is located at Rue Grande,Torgny 7, 6767 Rouvroy.

Is AMBROISE Vincent, médecine générale still active?

Yes. According to the CBE (18 September 2026) AMBROISE Vincent, médecine générale is active, legal situation “Normale toestand”, started on 7 November 2019.

Is AMBROISE Vincent, médecine générale registered on Peppol?

Yes, AMBROISE Vincent, médecine générale is registered on the Peppol network with ID 0208:0737495651.

What is the enterprise number of AMBROISE Vincent, médecine générale?

The enterprise number of AMBROISE Vincent, médecine générale is BE0737495651.

When was AMBROISE Vincent, médecine générale founded?

AMBROISE Vincent, médecine générale was founded on 7 November 2019.

Is AMBROISE Vincent, médecine générale a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 November 2019; 5 annual accounts filed, latest fiscal year 2025.

How much profit did AMBROISE Vincent, médecine générale make in 2025?

AMBROISE Vincent, médecine générale posted a profit after taxes of € 108,553 in financial year 2025.

What is the revenue of AMBROISE Vincent, médecine générale?

As a small company, AMBROISE Vincent, médecine générale is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 153,322.

AMBROISE Vincent, médecine générale (Private Limited)

Dossier AMBROISE Vincent, médecine générale, printed on 18 September 2026 from databakkes.be/en/0737495651/ambroise-vincent-medecine-generale. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

AMBROISE Vincent, médecine générale from Rouvroy, company number BE0737495651, closed financial year 2025 with a result of € 108,553 after tax. For that financial year AMBROISE Vincent, médecine générale recorded a gross margin of € 153,322 and equity of € 201,462. Compared with financial year 2024, the result moved from € 76,355 to € 108,553. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.

What it is worth Healthy

€ 201,462

▼ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 108,553

▲ 42% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 189,349

▲ 162% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 126,869 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 864

▼ 32% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 33,814

▼ 17% vs 2024

€ 7,117 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 238

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 27,654

▲ € 24,793 vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 266,181 Revenue 2022: € 266,181 First fiscal year in the series	€ 278,299 Revenue 2023: € 278,299 ▲ 5% vs 2022 (€ 266,181) Favourable step	-	-
Gross margin	€ 113,063 Gross margin 2022: € 113,063 First fiscal year in the series	€ 130,043 Gross margin 2023: € 130,043 ▲ 15% vs 2022 (€ 113,063) Favourable step	€ 131,495 Gross margin 2024: € 131,495 ▲ 1% vs 2023 (€ 130,043) Favourable step	€ 153,322 Gross margin 2025: € 153,322 ▲ 17% vs 2024 (€ 131,495) Favourable step	▲ 17%
Profit after taxes	€ 48,908 Profit after taxes 2022: € 48,908 First fiscal year in the series	€ 61,954 Profit after taxes 2023: € 61,954 ▲ 27% vs 2022 (€ 48,908) Favourable step	€ 76,355 Profit after taxes 2024: € 76,355 ▲ 23% vs 2023 (€ 61,954) Favourable step	€ 108,553 Profit after taxes 2025: € 108,553 ▲ 42% vs 2024 (€ 76,355) Favourable step	▲ 42%
Equity	€ 134,369 Equity 2022: € 134,369 First fiscal year in the series	€ 196,323 Equity 2023: € 196,323 ▲ 46% vs 2022 (€ 134,369) Favourable step	€ 219,778 Equity 2024: € 219,778 ▲ 12% vs 2023 (€ 196,323) Favourable step	€ 201,462 Equity 2025: € 201,462 ▼ 8% vs 2024 (€ 219,778) Unfavourable step	▼ 8%
Total debts	€ 70,945 Total debts 2022: € 70,945 First fiscal year in the series	€ 54,628 Total debts 2023: € 54,628 ▼ 23% vs 2022 (€ 70,945) Favourable step	€ 96,553 Total debts 2024: € 96,553 ▲ 77% vs 2023 (€ 54,628) Unfavourable step	€ 187,595 Total debts 2025: € 187,595 ▲ 94% vs 2024 (€ 96,553) Unfavourable step	▲ 94%
Cash	€ 124,549 Cash 2022: € 124,549 First fiscal year in the series	€ 209,567 Cash 2023: € 209,567 ▲ 68% vs 2022 (€ 124,549) Favourable step	€ 72,395 Cash 2024: € 72,395 ▼ 65% vs 2023 (€ 209,567) Unfavourable step	€ 189,349 Cash 2025: € 189,349 ▲ 162% vs 2024 (€ 72,395) Favourable step	▲ 162%
Retained profit	€ 126,869 Retained profit 2022: € 126,869 First fiscal year in the series	€ 188,823 Retained profit 2023: € 188,823 ▲ 49% vs 2022 (€ 126,869) Favourable step	€ 212,278 Retained profit 2024: € 212,278 ▲ 12% vs 2023 (€ 188,823) Favourable step	€ 193,962 Retained profit 2025: € 193,962 ▼ 9% vs 2024 (€ 212,278) Unfavourable step	▼ 9%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 52,900 Dividend 2024: € 52,900 Unchanged (€ 0) Unchanged	€ 126,869 Dividend 2025: € 126,869 ▲ 140% vs 2024 (€ 52,900) Unchanged	▲ 140%
Bank debt	€ 54,336 Bank debt 2022: € 54,336 First fiscal year in the series	€ 47,631 Bank debt 2023: € 47,631 ▼ 12% vs 2022 (€ 54,336) Favourable step	€ 40,792 Bank debt 2024: € 40,792 ▼ 14% vs 2023 (€ 47,631) Favourable step	€ 33,814 Bank debt 2025: € 33,814 ▼ 17% vs 2024 (€ 40,792) Favourable step	▼ 17%
Balance sheet total	€ 205,314 Balance sheet total 2022: € 205,314 First fiscal year in the series	€ 250,951 Balance sheet total 2023: € 250,951 ▲ 22% vs 2022 (€ 205,314) Unchanged	€ 316,331 Balance sheet total 2024: € 316,331 ▲ 26% vs 2023 (€ 250,951) Unchanged	€ 389,057 Balance sheet total 2025: € 389,057 ▲ 23% vs 2024 (€ 316,331) Unchanged	▲ 23%

Key figures of AMBROISE Vincent, médecine générale, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to AMBROISE Vincent, médecine générale?

What happened at AMBROISE Vincent, médecine générale in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 26, 2026 New annual accounts for financial year 2025: profit of € 108,553 (▲ 42% vs 2024). filed late Source: NBB ↗
Nov 7, 2019 New establishment in Aubange. KBO
Nov 7, 2019 Start of the company according to the CBE. KBO

In short

From € 48,908 profit in 2022 to € 108,553 profit in 2025.

Paid € 110,395 in corporate taxes since 2022.

Best year ever: 2025, with € 108,553 profit.

Paid out € 179,769 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at AMBROISE Vincent, médecine générale? We notify you, reason included.

Follow AMBROISE Vincent, médecine générale

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Grande,Torgny 7

6767 Rouvroy

2.296.791.734

Rue du Chalet - HALANZY 52

6792 Aubange

Active since 7 November 2019

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0737.495.651
VAT number: BE 0737.495.651
Registered office: Rue Grande,Torgny 7, 6767 Rouvroy
Names & denominations: AMBROISE Vincent, médecine générale
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 7 November 2019
Peppol: Active · Active since 24 Dec 2025
Activities · NACE: Activiteiten van huisartspraktijken

View on CBE Public ↗ Annual accounts (NBB) ↗

AMBROISE Vincent, médecine générale